决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Oral Manifestations and Management of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.
噬血细胞性淋巴组织细胞增生症(HLH)是一种严重、危及生命的高炎症综合征,其特征为细胞毒性T淋巴细胞和巨噬细胞的失调性激活,而淋巴瘤相关HLH(LA-HLH)由于诊断延迟和缺乏最佳治疗方案,预后尤其差。
噬血细胞性淋巴组织细胞增生症(HLH)是一种严重、危及生命的高炎症综合征,其特征是细胞毒性T淋巴细胞和巨噬细胞的失调性激活,而淋巴瘤相关HLH(LA-HLH)由于诊断延迟和缺乏最佳治疗方案,预后尤其差。虽然LA-HLH的全身特征——如持续发热、全血细胞减少和肝脾肿大——已有充分文献记载,但其口腔表现此前尚未在文献中描述。我们在此报告一例28岁女性LA-HLH患者,表现为间歇性发热伴反复口腔溃疡。该患者两年前被诊断为ENKTL(非鼻型,IVB期,PINK-E 4,高危),伴有皮肤和肌肉受累,并在化疗和自体造血干细胞移植后达到缓解。包括骨髓活检和实验室评估在内的全面诊断检查证实了继发于复发性结外NK/T细胞淋巴瘤(非鼻型,IVB期)的LA-HLH诊断。口腔病变采用康复新液漱口治疗,而 underlying lymphoma 和HLH则采用地塞米松和依托泊苷治疗,联合西达本胺和替雷利珠单抗。据我们所知,这是首例记录ENKTL累及口腔黏膜发生于LA-HLH患者的报告。这些口腔病变作为局限性淋巴瘤进展的表现,可能是淋巴瘤复发继发HLH的早期临床线索,而非LA-HLH本身的特异性早期体征。临床医生和牙医对这些潜在口腔表现的认识提高,有助于更早诊断LA-HLH患者的淋巴瘤复发,并改善相关并发症的多学科管理。
Hemophagocytic lymphohistiocytosis (HLH) is a severe, life-threatening hyperinflammatory syndrome characterized by dysregulated activation of cytotoxic T-lymphocytes and macrophages, with lymphoma-associated HLH (LA-HLH) carrying a particularly poor prognosis due to delayed diagnosis and lack of optimal treatment regimens. While the systemic features of LA-HLH-such as persistent fever, pancytopenia, and hepatosplenomegaly-are well-documented, its oral manifestations have not been previously described in the literature. We herein report a case of LA-HLH in a 28-year-old female patient who presented with intermittent fever along with recurrent oral ulcers. The patient had been diagnosed with ENKTL (non-nasal type, stage IVB, PINK-E 4, high risk) two years prior, with skin and muscle involvement, and had achieved remission after chemotherapy and autologous hematopoietic stem cell transplantation. A comprehensive diagnostic workup, including bone marrow biopsy and laboratory assessments, confirmed the diagnosis of LA-HLH secondary to relapsed extranodal NK/T-cell lymphoma (non-nasal type, stage IVB). The oral lesions were managed with Kangfuxin mouthwashes, while the underlying lymphoma and HLH were treated with dexamethasone and etoposide, combined with chidamide and tislelizumab. To the best of our knowledge, this is the first report documenting oral mucosal involvement by ENKTL occurring in a patient with LA-HLH. These oral lesions, as a manifestation of localized lymphoma progression, may serve as early clinical clues to lymphoma relapse with secondary HLH, rather than being a specific early sign of LA-HLH itself. Increased awareness of these potential oral findings among clinicians and dentists could facilitate earlier diagnosis of lymphoma relapse in LA-HLH patients and improve the multidisciplinary management of associated complications.
MEMBER ACCOUNT
登录成功会直接打开下一页。